Central Bank & Trust Co. Decreases Stake in Danaher Corporation $DHR

Key Points

• Central Bank & Trust Co. significantly reduced its stake in Danaher Corporation by 56.6%, now holding 1,322 shares valued at approximately $261,000.
• Danaher reported $1.80 earnings per share for the last quarter, surpassing estimates and showing a 3.4% revenue increase year-over-year, reaching $5.94 billion.
• The company announced a quarterly dividend of $0.32 per share, resulting in an annualized yield of 0.7%, with a payout ratio of 27.23%.

Central Bank & Trust Co. trimmed its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 56.6% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,322 shares of the conglomerate's stock after selling 1,727 shares during the quarter. Central Bank & Trust Co.'s holdings in Danaher were worth $261,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Nuveen LLC bought a new stake in shares of Danaher during the 1st quarter valued at about $833,941,000. GAMMA Investing LLC increased its stake in shares of Danaher by 24,958.2% during the first quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock valued at $383,524,000 after buying an additional 1,863,381 shares during the period. Invesco Ltd. increased its stake in shares of Danaher by 44.5% during the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after buying an additional 1,450,703 shares during the period. Baird Financial Group Inc. increased its stake in shares of Danaher by 290.6% during the first quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate's stock valued at $295,550,000 after buying an additional 1,072,617 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Danaher during the fourth quarter valued at approximately $242,837,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Price Performance

NYSE DHR traded down $1.96 during trading hours on Friday, reaching $193.31. The company's stock had a trading volume of 5,932,115 shares, compared to its average volume of 3,243,103. The company's 50-day moving average is $200.17 and its two-hundred day moving average is $198.30. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $279.90. The firm has a market capitalization of $138.42 billion, a price-to-earnings ratio of 41.13, a P/E/G ratio of 2.70 and a beta of 0.75. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm's revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period in the prior year, the business posted $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, September 26th. Danaher's payout ratio is currently 27.23%.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 2,778 shares of Danaher stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 11.10% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on DHR shares. Deutsche Bank Aktiengesellschaft reduced their price target on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Guggenheim reissued a "buy" rating and issued a $250.00 target price on shares of Danaher in a report on Wednesday, July 23rd. UBS Group reduced their price target on Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a research report on Wednesday, July 23rd. Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Finally, Wells Fargo & Company cut their target price on Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Danaher presently has a consensus rating of "Moderate Buy" and an average target price of $246.35.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.